Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan, R.O.C.
School of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.
Anticancer Res. 2021 Apr;41(4):2177-2182. doi: 10.21873/anticanres.14991.
BACKGROUND/AIM: To investigate the impact of PDZ-binding kinase (PBK) on the clinical outcome of patients with oral squamous cell carcinoma (OSCC) who received radiotherapy.
PBK immunoreactivity of cancer specimens obtained from 179 patients with primary OSCC was analyzed by immunohistochemistry.
High PBK expression in tumor cells tended to be associated with advanced N-stage. The 5-year survival rate was greater for patients with high total PBK expression than in those with low PBK expression. After adjustment, high PBK remained associated with a favorable outcome. In subgroups according to tumor stage, the prognostic role was significant in patients with stage III/IV rather than those with stage I/II disease.
We suggest that PBK expression should be used as an independent prognostic marker for patients with OSCC treated with radiotherapy, especially for those with advanced-stage disease.
背景/目的：研究 PDZ 结合激酶 (PBK) 对接受放疗的口腔鳞状细胞癌 (OSCC) 患者临床结局的影响。
通过免疫组织化学分析了 179 例原发性 OSCC 患者肿瘤标本中的 PBK 免疫反应性。
肿瘤细胞中高 PBK 表达与晚期 N 期有一定的相关性。高总 PBK 表达患者的 5 年生存率高于低 PBK 表达患者。经调整后，高 PBK 仍与良好的预后相关。根据肿瘤分期亚组分析，该预后作用在 III/IV 期患者中较为显著，而在 I/II 期患者中则不显著。
我们建议将 PBK 表达作为接受放疗的 OSCC 患者的独立预后标志物，尤其适用于晚期疾病患者。
